0226 GMT - Sigma Healthcare's recent share-price weakness only makes Morgans analyst Scott Power more bullish on the stock. Raising his recommendation on the Australian pharmaceutical wholesaler and retailer to buy from accumulate, Power tells clients in a note that he continues to anticipate annual earnings growth of about 20% over the next three years. He expects like-for-like sales growth, new domestic and international stores, operating efficiencies and the eventual delivery of A$100 million in annual synergies from 2025's merger between Sigma and the Chemist Warehouse retail chain. Morgans maintains its target price at A$3.36. Shares are down 0.7% at A$2.67. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 12, 2026 22:26 ET (02:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.